AVITA Medical to Present at the Piper Sandler 36th Annual Healthcare Conference
AVITA Medical to Present at the Piper Sandler 36th Annual Healthcare Conference
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.
加州瓦倫西亞，2024年11月25日(GLOBE NEWSWIRE) -- AVITA Medical, Inc. (納斯達克: RCEL，澳洲證券交易所: AVH)，一家專注於創新一線設備用於傷口護理管理和皮膚修復的商業階段再生醫學公司，宣佈首席執行官吉姆·柯貝特將於2024年12月3日星期二美東時間上午11:30參加派傑投資第36屆年度醫療保健會議。
A live webcast of the fireside chat will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.
現場網絡研討會可以在公司網站的「活動與演示」部分進行訪問。網絡研討會的重播將在活動結束後提供。
About AVITA Medical, Inc.
AVITA Medical is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and Cohealyx, an AVITA Medical-branded collagen-based dermal matrix.
AVITA Medical, Inc.是一家商業化階段的再生醫學公司。
AVITA Medical是一家商業化階段的再生醫學公司，通過創新的設備改變了創傷護理管理和皮膚修復的實踐標準。我們的平台的核心是RECELL系統，已獲得美國食品和藥物管理局批准，用於治療熱燒傷和全層皮膚缺陷，並用於穩定色素脫失白斑病變部位的再色素化。RECELL利用病人自身皮膚的再生能力，製造出噴霧狀皮膚細胞，爲現場提供一種改變的解決方案。這項突破性技術爲新的治療範式提供了催化劑，從而實現了改善臨床結果。在美國，AVITA Medical還擁有獨家銷售和分銷PermeaDerm，一種生物合成的創傷基質，以及Cohealyx，一種AVITA Medical品牌的膠原基質。
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit .
了解更多信息，請訪問 。
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
經 avita medical 公司首席財務官授權發佈。
CONTACT: Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com
聯繫人：投資者和媒體聯繫人：
Jessica Ekeberg
電話+1-661-904-9269
電子郵件investor@avitamedical.com
電子郵件media@avitamedical.com
譯文內容由第三人軟體翻譯。
